The agency told Bayer it needs additional time to review the non-hormonal drug, called elinzanetant. Regulators in Canada and ...

There is bipartisan consensus that drugs in the U.S. cost a lot more than in other high-income countries; therefore, it is important to comprehend how governmental interventions in other nations can ...